Eli Lilly and Co
Eli Lilly Stock Looks Like a Buy on Dips Amid Strong Growth Outlook
Eli Lilly Will Buy Prevail Therapeutics, COVID-19 Antibody Therapy Is Promising
Should You Buy Eli Lilly Stock After Its Q3 Earnings?
Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up
Wellington Management: Analyzing Its Top Holdings
Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.
How Are Citadel Advisors Hedging their Portfolio?
Kenneth Cordele Griffin is the CEO of investment management firm Citadel Advisors LLC. He is the hedge fund manager and he founded Citadel in 1990.
Tech Movers: Fitbit, Roku, and Datadog Lead Gains
The broader markets were subdued today. However, tech stocks Datadog (DDOG), Roku (ROKU) and Fitbit (FIT) gained significantly. Here’s why.
New Apple Watch Features to Focus on Digital Health
Apple (AAPL) has partnered with Eli Lily (LLY) to research whether the iPhone and Apple Watch can identify Alzheimer’s and dementia among users.
Pain and Immunology: Eli Lilly’s Key Growth Areas
In the first quarter, Emgality, Eli Lilly and Company’s (LLY) migraine prophylaxis drug, reported revenue of $14 million, of which $12.0 million came from the US market.
How Is Eli Lilly’s Revenue Trending in 2019?
During its first-quarter earnings investor presentation, Eli Lilly and Company (LLY) guided for revenue of $22.0 billion–$22.5 billion in 2019.
What Analysts Recommend for LLY and AMGN
Eli Lilly and Company (LLY) is down 0.20%, and Amgen (AMGN) is down 3.88% in 2019 on a year-to-date basis. Investors seem disappointed with the first-quarter results of both companies.
A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug
In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.
Why Analysts Still Favor Eli Lilly and Company Stock
Wall Street analysts have set Eli Lilly’s 12-month consensus target price at $122, 2.59% lower than the company’s closing price on March 18.
Why Eli Lilly Stock Fell Yesterday
Eli Lilly stock has been highly volatile since March 4.
What are AstraZeneca’s Key Growth Drivers?
In fiscal 2018, AstraZeneca’s (AZN) revenue fell 2% YoY (year-over-year) to $22.09 billion on a CER (constant-exchange-rate) and reported basis.
A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt
In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported effective tax rates of 3% and $15.98%, respectively.
Comparing AstraZeneca’s and Eli Lilly’s Dividends
In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported dividends per share of $1.40 and $2.25, respectively.
AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?
In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.
What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth
In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for core EPS of $3.50–$3.70 in fiscal 2019, expecting robust YoY (year-over-year) product sales growth and productivity improvements.
Analysts’ Recommendations for AstraZeneca and Eli Lilly
Most analysts recommend “buy” for AstraZeneca and Eli Lilly.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
ELAN or ZTS: Who Is Expected to Report Faster EPS Growth?
In its fourth-quarter earnings investor presentation, Elanco Animal Health (ELAN) reiterated its fiscal 2019 GAAP and non-GAAP EPS guidance of $0.36–$0.48 and $1.02–$1.12, respectively.
What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.
Moat Index: Dramatic Sector Allocation Shift in 2018
The healthcare sector dominated the sector weighting for the Morningstar Wide Moat Index in 2018. The sector returned ~5% in 2018.
What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?
In its fourth-quarter earnings investor presentation, Eli Lilly (LLY) highlighted its newer products such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz, Basaglar, Jardiance, Trulicity, and Cyramza as its key drivers.
Pfizer and Eli Lilly: How Dividends and Tax Rates Stack Up
Pfizer (PFE) and Eli Lilly (LLY) reported dividends per share of $1.36 and $2.25 in fiscal 2018, respectively.
Pfizer or Eli Lilly: Who Is Controlling Expenses Better?
In its fourth-quarter earnings investor presentation, Pfizer (PFE) guided for adjusted cost of sales as a percentage of revenues of 20.8% to 21.8% for fiscal 2019.
Pfizer or Eli Lilly: Who Is Expected to Report Higher EPS Growth?
In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for non-GAAP diluted EPS of $2.82–$2.92 for fiscal 2019 excluding the impact of profits and losses associated with equity investments.
Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?
In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.
What Analysts Recommend for Pfizer and Eli Lilly in February
Since its fourth-quarter earnings release, Pfizer stock has risen 4.48%.
Eli Lilly and Loxo: A Robust Oncology Pipeline for Future Years
Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.
Loxo Oncology Is Expected to Boost Eli Lilly’s Revenue in 2019
Eli Lilly and Company (LLY) expects its Loxo Oncology (LOXO) acquisition to become revenue accretive starting in 2019.
What Are Analysts Recommending for Eli Lilly and Loxo Oncology?
Eli Lilly and Company (LLY) has entered into an agreement to acquire Loxo Oncology (LOXO) for a net consideration of $7.2 billion.
Pfizer or Eli Lilly: Which Company Has the Better Dividend Policy?
On its third-quarter earnings conference call, Pfizer (PFE) reported the return of $15.0 billion in dividends by way of share repurchases as of the end of October 2018.
Pfizer or Eli Lilly: Which Company Is More Cost Efficient?
On its third-quarter earnings conference call, Pfizer (PFE) said it expected its cost of sales as a percentage of its revenue to fall in the range of 20.8%–21.3%.
Pfizer or Eli Lilly: Which Company Has Better Margins?
In November 2018, Pfizer announced a hike in the list prices of 10% (or 41) of the medicines in its drug portfolio starting on January 15, 2019.
Pfizer or Eli Lilly: Whose Earnings Are Seeing Better Growth?
On its third-quarter earnings conference call, Pfizer (PFE) said that it expected its 2018 adjusted EPS to be in the range of $2.98–$3.02.
Pfizer or Eli Lilly: Whose Revenue Is Growing More Quickly?
On its third-quarter earnings conference call, Pfizer (PFE) narrowed its 2018 revenue guidance range to $53.0 billion–$53.7 billion.
Analysts’ Recommendations for Eli Lilly in January
Eli Lilly and Company (LLY) is a leading large pharmaceutical company with a total market cap of $117.91 billion.
Why Loxo Oncology Has Surged More than 65% Today
Earlier today, American pharmaceutical giant Eli Lilly and Company (LLY) announced its acquisition of Loxo Oncology (LOXO).
This Drug Is Expected to Be a Significant Driver for Pfizer
In the first nine months of this year, Pfizer’s (PFE) Ibrance revenue grew 24% YoY (year-over-year) to $3.0 billion from $2.4 billion.
Do Analysts See Any Upside for Ionis Stock?
Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”
Taking Stock of Ionis’s Performance
Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.
Do Analysts See Any Upside for Biogen Stock?
Of the 29 analysts covering Biogen (BIIB), 20 have given it “buy” or higher ratings, and nine have given it “hold” ratings.
What Seattle Genetics’ Bottom-Line Trend Indicates
In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.
How’s Seattle Genetics Positioned?
Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
Ajovy Is a New Growth Driver for Teva Pharmaceutical
On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy.
Analyzing Eli Lilly’s Stock Price and Financial Performance
On November 16, Eli Lilly’s (LLY) stock price closed at $113.83, which represents ~1.45% growth from its close of $112.20 on November 15.
Gauging Analysts’ Views on Clovis Stock
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
A Look at Merck’s Diabetes and Women’s Health Business
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.
Pfizer Missed Analysts’ Third-Quarter Revenue Estimates
Pfizer (PFE) released its third-quarter earnings on October 30.
Sanofi: Analysts’ Recommendations on October 30
As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”
A Look at the Performances of BMY’s Established Brands
The sales of Bristol-Myers Squibb’s Baraclude fell from $264.0 million in the third quarter of 2017 to $175.0 million in the third quarter of 2018.
How JNJ’s Invega Sustenna and Risperdal Consta Performed
Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.
Pfizer: Analysts Expect Revenue Growth in Q3
Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.
What’s Pfizer’s Current Valuation?
Pfizer is trading at a forward PE ratio of ~14.5x on October 18—compared to the industry average of ~15.7x.
Pfizer’s Dividends and Earnings Quality
Pfizer’s dividend yield is 3.15%. The company’s historical dividend yield was 3.53% in 2017, while the five-year average yield is 3.44%.
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Pfizer’s Market Cap and Shareholding Pattern
Pfizer’s total shares outstanding are ~5.862 billion. There are ~5.859 billion free-floating shares—nearly 99.95% of the total outstanding shares.
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17.
What’s Expected for Merck’s Q3 2018 Earnings
Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
Investor Insights: Teva Pharmaceutical’s Valuation Multiples
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.
A Look at Novartis’s Valuation on October 9
Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue.
Assessing Novartis’s Performance in October So Far
Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.
Amgen’s Stock Performance and Estimates after Q3 2018
Analysts expect Amgen’s (AMGN) stock price to fall ~1.4% over the next 12 months.
How Did Pfizer Stock Fare in Q3 2018?
Nineteen analysts currently track Pfizer stock. The consensus rating for Pfizer stands at 2.63, which represents a “hold.”
Eli Lilly’s Stock Performance and Estimates for Q3 2018
Sixteen analysts currently track Eli Lilly (LLY) stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.”
Mylan Launches Its Generic Brevibloc Injection
Mylan announced the launch of its generic Brevibloc injection in single-dose bags on September 13.
Does Mylan’s Low Valuation Provide a ‘Buy’ Opportunity?
On September 26, Mylan had a 12-month forward PEG ratio of ~0.94x.
Teva Announces First-to-File Launch of Generic Cialis
Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.
How GlaxoSmithKline’s Pharmaceutical Business Performed
GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.
Sanofi Stock Up 2.8% in September: What Lies Ahead?
On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.
Sanofi Stock: How Much Upside Potential Does Wall Street See?
In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.
A Look at Elanco, Eli Lilly’s Animal Health Business
Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.
How Eli Lilly’s Cardiovascular Products Have Been Faring
Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.
Eli Lilly’s Earnings Quality and Dividend Performance
Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.
Eli Lilly’s Market Cap and Shareholding Pattern
Eli Lilly and Company’s (LLY) market cap is ~$106.0 billion as of September 26.
What’s Eli Lilly’s Valuation as of September 27?
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.
Eli Lilly’s Stock Performance in September
Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.
Comparing Pfizer Stock and Eli Lilly Stock
Eli Lilly and Company (LLY) stock has fallen a marginal ~0.1% so far in September, and its closing price was $105.59 on September 24.
Comparing Pfizer Stock and Merck and Co. Stock
Merck & Co. (MRK) stock has risen ~3.2% in the same period, with a closing price of $70.78 on September 24.
A Look at Pfizer’s Market Cap and Shareholding Pattern
The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.
Assessing Pfizer’s Global Performance
Pfizer reported a rise in revenue in international markets in the second quarter, though this growth was offset by lower sales in US markets.
Pfizer’s Revenue and EPS Growth Rate
Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate.
What’s Driving Pfizer’s Revenue?
Pfizer has divided its product portfolio into two segments: Innovative Health and Essential Health. It reports revenue for both these segments.
Analyzing Perrigo’s Spin-Off of Its Rx Business
In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.
A Look at Eli Lilly’s Elanco Spin-Off
Eli Lilly (LLY) is expected to post revenues of $24.33 billion in fiscal 2018 and $24.8 billion in fiscal 2019.
Allergan’s SpotLyte and Lumivive System
SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
A Closer Look at the Allergan–Bonti Deal
On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.
Allergan’s Stock Price Performance in September
On September 21, 23 analysts tracked Allergan (AGN) stock. Four analysts recommended a “strong buy,” and 12 analysts recommended a “buy.”
Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates
Allergan (AGN) reported revenue of $4.1 billion in the second quarter, a 2.9% YoY (year-over-year) rise in revenue.
Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates
Merck & Co. (MRK) reported revenue of ~$10.5 billion in the second quarter, a 5% YoY (year-over-year) rise in revenue.
Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates
Pfizer (PFE) reported revenue of ~$13.5 billion in the second quarter, a 4% YoY (year-over-year) rise in revenue.
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Exploring Pharmaceutical Stocks’ Revenue Growth Rates
In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series.
A Look at the Dividends Paid by Pharma Stocks in 2018
In this article, we’ll discuss the details of the dividends paid by the pharmaceutical stocks under review in this series.
How Pharmaceutical ETFs Have Performed in 2018
The SPDR S&P Pharmaceuticals ETF holds ~5.0% of its total investments in Eli Lilly and Company (LLY).
These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
Pharmaceutical stocks that have surpassed the S&P 500 Index’s returns YTD include Eli Lilly, Pfizer, Merck, Allergan, and GlaxoSmithKline.